MDHAQ/RAPID3 scores quantitative patient history data in a standardized "scientific" format for optimal assessment of patient status and quality of care in rheumatic diseases

Bulletin of the NYU Hospital for Joint Diseases

Volumn 69, Issue 3, 2011, Pages 201-214

  Pincus, Theodore ^a   Castrejón, Isabel ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; DNA ANTIBODY; HEMOGLOBIN A1C; RHEUMATOID FACTOR;

CLINICAL RESEARCH; DEMOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEASIBILITY STUDY; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE QUALITY; HEMATOCRIT; HUMAN; LABORATORY TEST; MEDICAL HISTORY; MEDICAL RECORD; MONITORING; PATIENT ASSESSMENT; PHYSICAL EXAMINATION; PHYSICIAN; QUESTIONNAIRE; REVIEW; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; VISUAL ANALOG SCALE;

HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; MEDICAL HISTORY TAKING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE; QUESTIONNAIRES; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 80054108467     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Hampton JR, Harrison MJG, Mitchell JRA, et al. Relative contributions of history-taking, physical examination, and laboratory investigation to diagnosis and management of medical outpatients. Br Med J. 1975; 2:486-9.
2. Sandler G. The importance of the history in the medical clinic and the cost of unnecessary tests. Am Heart J. 1980;100(6 Pt 1):928-31.
3. Peterson MC, Holbrook JH, Hales DV, et al. Contributions of the history, physical examination, and laboratory investigation in marking medical diagnoses. West J Med. 1992;56:163-5.
4. Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med. 1993;118:81-90.
5. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-45.
6. Meenan RF, Gertman PM, Mason JH, Dunaif R. The arthritis impact measurement scales: further investigations of a health status measure. Arthritis Rheum. 1982;25:1048-53.
7. Pincus T, Summey JA, Soraci SA Jr, et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum. 1983;26:1346-53.
8. Stucki G, Liang MH, Stucki S, et al. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Arthritis Rheum. 1995;38:795-8.
9. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional health assessment questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. Arthritis Rheum. 1999;42:2220-30.
10. Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a multidimensional health assessment questionnaire for standard care of patients with rheumatic diseases. J Rheumatol. 2005;32:1432-9.
11. Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med. 1980;93:551-6.
12. Sokka T, Pincus T. Markers for work disability in rheumatoid arthritis. J Rheumatol. 2001;28:1718-22.
13. Chung CP, Sokka T, Arbogast P, Pincus T. Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis. 2006;65(12):1653-7.
14. Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-72.
15. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S35-S61.
16. Sokka T, Pincus T. Poor physical function, pain and limited exercise: risk factors for premature mortality in the range of smoking or hypertension, identified on a simple patient self report questionnaire for usual care. BMJ Open. 18 June 2011. doi:10.1136/bmjopen-2011-000070.
17. Pincus T, Amara I, Segurado OG, et al. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008;35(2):201-205.
18. Pincus T, Bergman MJ, Yazici Y, et al. An index of only patient reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford). 2008;47(3):345-349.
19. Pincus T, Oliver AM, Bergman MJ. How to collect an MDHAQ to provide rheumatology vital signs (function, pain, global status, and RAPID3 scores) in the infrastructure of rheumatology care, including some misconceptions regarding the MDHAQ. Rheum Dis Clin North Am. 2009;35(4):799-812.
20. Pincus T, Sokka T. Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am. 2009;35(4):731-734.
21. Pincus T. A multidimensional health assessment questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care. Bull NYU Hosp Jt Dis. 2007;65(2):150-60.
22. Pincus T, Yazici Y, Bergman MJ. Beyond RAPID3 practical use of the MDHAQ to improve doctor-patient communication. Bull NYU Hosp Jt Dis. 2010;68(3):223-31.
23. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808.
24. Sokka, T, Pincus T., Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol. 2009;36(7):1387-90.
25. Rose HM, Ragan C, Pearce E, Lipman MO. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med. 1948;68:1-6.
26. Seligmann M. Serologie mise en evidence dan le serum des malades atteints de Lupus erythemateux, dissemine d'une substance determinant une reaction de precipitation avec l'acide desoxyribonucleique. Compt Rend Acad Sci (Paris). 1957;245:243-5.
27. Holman HR, Kunkel HG. Affinity between the lupus erythematosus serum factor and cell nuclei and nucleoprotein. Science. 1957;126:162.
28. Ceppellini R, Polli E, Celada F. A DNA-reacting factor in serum of a patient with lupus erythematosus diffusus. Proc Soc Exp Biol Med. 1957;96(3):572-4.
29. Goldsmith CH, Smythe HA, Helewa A. Interpretation and power of pooled index. J Rheumatol. 1993;20:575-578.
30. van Riel PLCM. Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis (Editorial). Br J Rheumatol. 1992;31:793-4.
31. Tugwell, P, Boers M., OMERACT Committee. Proceedings of the OMERACT Conferences on outcome measures in rheumatoid arthritis clinical trials, Maastrict, Netherlands. J Rheumatol. 1993;20:527-91.
32. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36:729-40.
33. van der Heijde DMFM, van't Hof M, van Riel PLCM, van de Putte LBA. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993;20:579-81.
34. Prevoo MLL, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8.
35. Fleischer JAB, Feldman SR, Rapp SR, et al. Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. J Invest Dermatol. 1996;107:26-9.
36. Kavanaugh A, Cassell S. The assessment of disease activity and outcomes in psoriatic arthritis. Clin Exp Rheumatol. 2005;23:S142-S147.
37. Hawker G, Gabriel S, Bombardier C, et al. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol. 1993;20:657-60.
38. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86(7):447-58.
39. Swaak AJ, van den Brink HG, Smeenk RJ, et al. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus. 2001;10(1):51-8.
40. Petri M, Hellmann DB, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol. 1992;19:53-9.
41. Mosca M, Bencivelli W, Vitali C, et al. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus. 2000;9(6):445-50.
42. Bencivelli W, Vitali C, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992;10(5):549-54.
43. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363-9.
44. Calin A, Nakache JP, Gueguen A, et al. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford). 1999;38(9):878-82.
45. Creemers MC, Franssen MJ, van't Hof MA, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64(1):127-9.
46. Calin A, MacKay K, Santos H, Brophy S. A new dimension to outcome: application of the Bath Ankylosing Spondylitis Radiology Index. J Rheumatol. 1999;26(4):988-92.
47. Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J 66. Pincus T. Ammonium sulphate precipitation to measure antibody Rheumatol. 1994;21(12):2281-5.
48. Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS metrology index. J Rheumatol. 1994;21(9):1694-1698.
49. Dougados M, Gueguen A, Nakache JP, et al. Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol. 1988;15:302-307.
50. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasc-litis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med. 1994;87:671-678.
51. Whiting O'Keefe QE, Stone JH, Hellmann DB. Validity of a vasculitis activity index for systemic necrotizing vasculitis. Arthritis Rheum. 1999;42:2365-2371.
52. Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum. 2001;44:912-920.
53. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371-380.
54. Seo P, Min Y, Holbrook JT, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trail (WGET). Arthritis Rheum. 2005;52:2168-2178.
55. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833-1840.
56. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991;18:728-733.
57. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277-299.
58. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191-197.
59. Brown GK, Nicassio PM. Development of a questionnaire for the assessment of active and passive coping strategies in chronic pain patients. Pain. 1987;31:53-64.
60. Bombardier C, Hayden J, Beaton DE. Minimal clinically important difference. Low back pain: outcome measures. J Rheumatol. 2001;28(2):431-438.
61. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121-1123.
62. Smets EM, Garssen B, Bonke B, de Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;22:315-325.
63. Cella D. The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34:13-19.
64. Pincus T, Schur PH, Rose JA, et al. Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med. 1969;281:701-705.
65. Pincus T. Citation Classic [Pincus T, Schur PH, Rose JA, Decker JL, Talal N. Measurement of serum DNA-binding in activity in systemic lupus erythematosus. New Eng J Med 281:701-705, 1969.] Current Contents: Clinical Practice 1983;11:18.
66. Pincus T. Ammonium sulphate precipitation to measure antibodies to double-stranded DNA: a simple clinical test for diagnosis and management of patients with systemic lupus erythematosus. Lupus. 2009;18(14):1243-5.
67. Fuchs HA, Brooks RH, Callahan LF, Pincus T. A simplified twenty-eight joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum. 1989;32:531-7.
68. Fuchs HA, Pincus T. Reduced joint counts in controlled clinical trials in rheumatoid arthritis. Arthritis Rheum. 1994;37:470-5.
69. Smolen JS, Breedveld FC, Eberl G, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum. 1995;38:38-43.
70. Landewe R, van der Heijde D, van der Linden S, Boers M. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis. 2006;65:637-641.
71. Pincus T, Maclean R, Yazici Y, Harrington JT. Quantitative measurement of patient status in the regular care of patients with rheumatic diseases over 25 years as a continuous quality improvement activity, rather than traditional research. Clin Exp Rheumatol. 2007;25(6 Suppl 47):S69-S81.
72. Pincus T, Yazici Y, Bergman M, et al. A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative Routine Assessment of Patient Index Data (RAPID) scores on a Multidimensional Health Assessment Questionnaire (MDHAQ). Best Pract Res Clin Rheumatol. 2007;21(4):789-804.
73. Pincus T, Yazici Y, Bergman M, et al. A proposed approach to recognise "near remission" quantitatively without formal joint counts or laboratory tests: a patient self-report questionnaire routine assessment of patient index data (RAPID) score as a guide to a "continuous quality improvement" strategy. Clin Exp Rheumatol. 2006;24(S43):S60-S73.
74. Berwick DM. Sounding Board: continuous improvement as an ideal in health care. N Engl J Med. 1989;320:53-6.
75. Berwick DM. A primer on leading the improvement of systems. Br Med J. 1996;312:619-622.
76. Pincus T, Swearingen CJ, Bergman MJ, et al. RAPID3 on an MDHAQ is correlated significantly with activity levels of DAS28 and CDAI, but scored in 5 versus more than 90 seconds. Arthritis Care Res. 2010;62(2):181-189.
77. Pincus T, Bergman M, Sokka T, et al. Visual analog scales in formats other than a 10 centimeter horizontal line to assess pain and other clinical data. J Rheumatol. 2008;35(8):1550-1558.
78. Pincus T, Askanase AD, Swearingen CJ. A multi-dimensional health assessment questionnaire (MDHAQ) and routine assessment of patient index data (RAPID3) scores are informative in patients with all rheumatic diseases. Rheum Dis Clin North Am. 2009;35(4):819-827.
79. Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am. 2009;35(4):773-778.
80. Pincus T, Mandelin AM, Swearingen CJ. Flowsheets that include MDHAQ physical function, pain, global, and RAPID3 scores, laboratory tests, and medications to monitor patients with all rheumatic diseases: an electronic database for an electronic medical record. Rheum Dis Clin North Am. 2009;35(4):829-842.